GlassScriptPhysician profile
Fisayo Tunde
NPI 1881195881
$1,450.91
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $382 · 2021: $19.70 · 2022: $180 · 2023: $138 · 2024: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $225 · Food and Beverage: $131 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $225.00 |
| Food and Beverage | $131.19 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $679.00 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.27 | 2019-2024 | |
| Abbvie INC. | $93.33 | 2019-2022 | |
| Exeltis, USA INC. | $70.06 | 2019-2023 | Nuvessa, Slynd |
| Mayne Pharma Commercial LLC | $54.17 | 2022-2023 | |
| Pfizer INC. | $53.10 | 2023 | |
| Daiichi Sankyo INC. | $45.79 | 2019-2020 | |
| Avion Pharmaceuticals | $27.46 | 2019-2022 | |
| Hologic Sales and Service, LLC | $20.03 | 2022 | |
| Therapeuticsmd, INC. | $19.49 | 2019 | |
| Sumitomo Pharma America, INC. | $16.24 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $14.99 | 2022 | |
| Agile Therapeutics, INC. | $14.28 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.23 | 2019 | |
| Merck Sharp & Dohme LLC | $13.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.60 | 2019 | |
| Organon LLC | $12.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fisayo Tunde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.